Revisions to WHO guidelines for antiretroviral treatment of adults and adolescents
2009 update
Programmatic experience and new scientific evidence have accumulated since release of the 2006 WHO guidelines for antiretroviral treatment of adults and adolescents and those for treating HIV-infected pregnant women and preventing HIV infection in infants. WHO is reviewing these developments with the aim of revising and updating recommendations on these subjects in a coordinated fashion.
Links to the 2006 guidelines:
Adults and adolescents |
Pregnant women and infants
A summary of the process and timelines being followed for the coordinated revision of these guidelines is provided below.
See also:
Revisions to WHO guidelines for antiretroviral treatment of pregnant women and prevention of HIV infection in infants
WHO ART guideline revision process
Populations being considered
- HIV+ adults and adolescents
- HIV+ pregnant women
- HIV+ with TB co-infection
- HIV+ with Hepatitis B co-infection
- HIV+ with Hepatitis C co-infection
- HIV+ drug user
- HIV+ child 1yr or over
Areas for review
- How to diagnose earlier?
- How to monitor?
- When to start?
- What to use 1st line?
- What to use 2nd line?
- Third line?
Relevant outcomes
- Mortality
- Disease progression (morbidity)
- Severe or regimen limiting adverse events
- Adherence and retention on ART
- Durability of regimen effect
- Reduction of HIV transmission
- Cost
- CD4
- HIV viral load
- HIV drug resistance
Ideal recommendations
- One 'when to start criteria' for all populations
- One 'preferred regimen' for all patients
- One 'preferred second line regimen' for all patients failing first line
- Maximise patient and public health outcome benefits at smallest risk and contain costs